• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Polyrizon Ltd. - Ordinary Shares (NQ:PLRZ)

    10.28 -0.31 (-2.93%)
    Streaming Delayed Price Updated: 3:53 PM EDT, Aug 4, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Polyrizon Ltd. - Ordinary Shares

    < Previous 1 2 3 4 5 6 7 8 9 Next >
    News headline image
    Polyrizon Announces Successful Results for NASARIX™ Biocompatibility Program, Supporting Advancement Towards First in Human Clinical Trial
    From Polyrizon Ltd.
    Via GlobeNewswire
    News headline image
    Polyrizon Makes Strong Progress: Receives Central IRB Approval for its Allergy Blocker Clinical Trial
    From Polyrizon Ltd.
    Via GlobeNewswire
    News headline image
    Polyrizon Receives Notice of U.S. Patent Publication for Mucoadhesive Drug Delivery Platform
    From Polyrizon Ltd.
    Via GlobeNewswire
    News headline image
    Polyrizon Advances NASARIX™ Development with Key Human Study to Characterize Nasal Residence Time and Support FDA Regulatory Pathway
    From Polyrizon Ltd.
    Via GlobeNewswire
    PLRZ Stock Jumps 6% In Pre-Market – Why Is This Biotech Firm Diversifying Into Aviation Business? ↗
    Via Stocktwits
    News headline image
    Polyrizon Receives Notice of European Patent Publication for Innovative Mucoadhesive Nasal Drug Delivery Technology
    From Polyrizon Ltd.
    Via GlobeNewswire
    News headline image
    Polyrizon Makes Strong Clinical Progress: Secures Three U.S. Sites for NASARIX™ Trial
    From Polyrizon Ltd.
    Via GlobeNewswire
    News headline image
    Polyrizon Advances Towards Human Clinical Trials: Secures First U.S. Clinical Site for NASARIX™ Allergy Blocker Clinical Trial
    From Polyrizon Ltd.
    Via GlobeNewswire
    News headline image
    Polyrizon Announces U.S. Patent Expansion for Its Intranasal Drug Delivery Platform
    From Polyrizon Ltd.
    Via GlobeNewswire
    News headline image
    Polyrizon Announces Filing of European Patent Application for Its Breakthrough Drug Delivery Platform
    From Polyrizon Ltd.
    Via GlobeNewswire
    TechMediaBreaks – Polyrizon Ltd. (NASDAQ: PLRZ) Closes $3.5 Million Registered Direct Offering and Concurrent Private Placement
    Via Investor Brand Network
    News headline image
    Polyrizon Ltd. Announces $3.5 Million Registered Direct Offering and Private Placement
    From Polyrizon Ltd.
    Via GlobeNewswire
    News headline image
    Polyrizon Provides 2025 and Recent Highlights
    Company Concluded 2025 with Robust Cash Position, Debt-Free Balance Sheet and Significant Pipeline Achievements 
    From Polyrizon Ltd.
    Via GlobeNewswire
    News headline image
    Polyrizon Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2025
    From Polyrizon Ltd.
    Via GlobeNewswire
    News headline image
    Polyrizon Intends to Acquire up to 20% Stake in Colugo, Developer of Advanced eVTOL Drones for Defense and Urban Air Mobility Applications
    From Polyrizon Ltd.
    Via GlobeNewswire
    News headline image
    Polyrizon Signs an Agreement with Leading Global Preclinical CRO as Part of Clinical Development Program
    From Polyrizon Ltd.
    Via GlobeNewswire
    News headline image
    Polyrizon Announces GMP Manufacturing of Clinical Trial Material (CTM) with Eurofins CDMO AmatsiAquitaine S.A.S for Planned U.S. Clinical Study
    From Polyrizon Ltd.
    Via GlobeNewswire
    News headline image
    Polyrizon Announces Successful Study of its Naloxone Formulation Demonstrating Enhanced Nasal Deposition Profile Versus Commercial Reference Product
    From Polyrizon Ltd.
    Via GlobeNewswire
    News headline image
    Polyrizon Intends to Secure Controlling Stake in Profitable Private Jet Operator
    From Polyrizon Ltd.
    Via GlobeNewswire
    News headline image
    Polyrizon Signs an Agreement to Develop Intranasal Proprietary Non-Hallucinogenic Neuroplastogen Formulation
    From Polyrizon Ltd.
    Via GlobeNewswire
    News headline image
    Clearmind Medicine Enters into Development Agreement to Advance Intranasal Formulation for its Proprietary Non-Hallucinogenic Neuroplastogen MEAI
    From Clearmind Medicine Inc.
    Via GlobeNewswire
    News headline image
    Polyrizon Intends to Acquire 51% Stake in Global Private Aviation Company
    From Polyrizon Ltd.
    Via GlobeNewswire
    Top movers in Monday's session ↗
    Via Chartmill
    Monday's session: top gainers and losers ↗
    Via Chartmill
    News headline image
    Polyrizon Advances Regulatory Path with Initiation of Usability Study Program for NASARIX™ Allergy Blocker
    From Polyrizon Ltd.
    Via GlobeNewswire
    News headline image
    Polyrizon to Explore Revenue-Generating Investment Opportunities in High-Growth Sectors, Leveraging Strong Cash Position and Debt-Free Balance Sheet
    From Polyrizon Ltd.
    Via GlobeNewswire
    News headline image
    Polyrizon Completes Branding Process for PL-14 Allergy Blocker with Brand Name NASARIX™
    From Polyrizon Ltd.
    Via GlobeNewswire
    News headline image
    Polyrizon Announces New Pre-Clinical Results: PL-14 Demonstrates Significant Allergen-Blocking Performance Compared to a Standard Comparator
    From Polyrizon Ltd.
    Via GlobeNewswire
    Wondering what's happening in today's pre-market session? ↗
    Via Chartmill
    Top stock movements in today's session. ↗
    Via Chartmill
    < Previous 1 2 3 4 5 6 7 8 9 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.